Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Super-enhancer-mediated regulation of CD38 inducibility in multiple myeloma via the MAF/TRIM47/RARα axis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZDZhenfeng DaiQSQiqi ShenJZJianbiao Zhou

Discussion

Loading...

Member takes

Overview

Analysis reveals that targeting TRIM47 may improve immunotherapy efficacy by stabilizing RARα in multiple myeloma.

Key Points

  • Tumor regression was significantly improved in shTRIM47 myeloma models when treated with ATRA, facilitating CD38 expression.
  • In vitro findings showed that TRIM47 knockdown enhanced CAR-T cytotoxicity and cytokine production, indicating a vital regulatory role.
  • Super-enhancer analysis identified MAF as a major transcription factor influencing TRIM47 expression in multiple myeloma.
  • Targeting the MAF-TRIM47-RARα axis opens new therapeutic strategies for patients with high-risk multiple myeloma.

Cite This Study

Dai et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db6ehttps://doi.org/10.1182/blood-2025-2156
View Full Paper
Ask AI
Bookmark
Share